811 related articles for article (PubMed ID: 24565522)
21. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
Chan JK; Pham H; You XJ; Cloven NG; Burger RA; Rose GS; Van Nostrand K; Korc M; Disaia PJ; Fan H
Cancer Res; 2005 Apr; 65(8):3243-8. PubMed ID: 15833856
[TBL] [Abstract][Full Text] [Related]
22. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.
Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J
Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192
[TBL] [Abstract][Full Text] [Related]
23. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
24. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
Baghbani F; Moztarzadeh F
Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
[TBL] [Abstract][Full Text] [Related]
25. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
26. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin-loaded, Sialyl Lewis X-Modified Liposomes: Drug Release, Biodistribution and Antitumor Efficacy.
Kishimoto S; Fujitani N; Ohnishi T; Aoki H; Suzuki R; Fukushima S
Anticancer Res; 2017 Nov; 37(11):6055-6061. PubMed ID: 29061785
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
Kalli KR; Bradley SV; Fuchshuber S; Conover CA
Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
[TBL] [Abstract][Full Text] [Related]
29. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
31. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo.
Lee CM; Tanaka T; Murai T; Kondo M; Kimura J; Su W; Kitagawa T; Ito T; Matsuda H; Miyasaka M
Cancer Res; 2002 Aug; 62(15):4282-8. PubMed ID: 12154030
[TBL] [Abstract][Full Text] [Related]
32. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
33. A cisplatin‑incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity.
Jung J; Jeong SY; Park SS; Shin SH; Ju EJ; Choi J; Park J; Lee JH; Kim I; Suh YA; Hwang JJ; Kuroda S; Lee JS; Song SY; Choi EK
Int J Oncol; 2015 Mar; 46(3):1268-74. PubMed ID: 25544240
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy.
Riaz MK; Zhang X; Wong KH; Chen H; Liu Q; Chen X; Zhang G; Lu A; Yang Z
Int J Nanomedicine; 2019; 14():2879-2902. PubMed ID: 31118613
[No Abstract] [Full Text] [Related]
36. Reversal of multidrug resistance in human lung cancer cells by delivery of 3-octadecylcarbamoylacrylic acid-cisplatin-based liposomes.
Song J; Ren W; Xu T; Zhang Y; Guo H; Zhu S; Yang L
Drug Des Devel Ther; 2017; 11():441-449. PubMed ID: 28255230
[TBL] [Abstract][Full Text] [Related]
37. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
[TBL] [Abstract][Full Text] [Related]
38. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors.
Ding D; Zhu Z; Liu Q; Wang J; Hu Y; Jiang X; Liu B
Eur J Pharm Biopharm; 2011 Sep; 79(1):142-9. PubMed ID: 21272637
[TBL] [Abstract][Full Text] [Related]
40. Protein release kinetics for core-shell hybrid nanoparticles based on the layer-by-layer assembly of alginate and chitosan on liposomes.
Haidar ZS; Hamdy RC; Tabrizian M
Biomaterials; 2008 Mar; 29(9):1207-15. PubMed ID: 18076987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
